Table 2. The prevalence of resistance to first and second line anti-TB drugs among M.
tuberculosis isolates from new and previously treated cases of tuberculosis.
| New cases | Previously treated Cases | |||
|---|---|---|---|---|
| (n = 1220) | (n = 714) | |||
| Numbers (%) | 95% CI | Numbers (%) | 95% CI | |
| Susceptible to all drugs | 976 (80.0) | 77.8–82.2 | 444 (62.2) | 58.5–65.7 |
| Any Resistance | ||||
| Isoniazid | 127 (10.4) | 8.7–12.1 | 214 (30.0) | 26.7–33.4 |
| Rifampicin | 32 (2.6) | 1.7–3.5 | 108 (15.1) | 12.6–17.9 |
| Kanamycin | 1 (0.1) | 0.0–0.2 | 7 (1.0) | 0.3–1.9 |
| Ofloxacin | 127 (10.4) | 8.7–12.1 | 99 (13.9) | 11.4–16.5 |
| Mono Resistance | ||||
| Isoniazid | 91 (7.5) | 6.0–8.9 | 95 (13.3) | 10.8–15.8 |
| Rifampicin | 8 (0.7) | 0.2–1.1 | 11 (1.5) | 0.6–2.4 |
| Kanamycin | 0.0 | 0.0 | 1 (0.1) | 0.0–0.4 |
| Ofloxacin | 107 (8.8) | 7.2–10.4 | 41 (5.7) | 4.0–7.4 |
| Combined resistance | ||||
| Ofloxacin +Rifampicin | 2 (0.2) | 0.0–0.4 | 3 (0.4) | 0.0–0.9 |
| Ofloxacin + Isoniazid | 14 (1.1) | 0.5–1.7 | 24 (3.4) | 2.0–4.7 |
| Isoniazid+Kanamycin | 0 | 0.0 | 1 (0.1) | 0.0–0.4 |
| MDR | 22 (1.8) | 1.1–2.5 | 94 (13.2) | 10.7–15.6 |
| Isoniazid +Rifampicin | 17 (1.4) | 0.7–2.1 | 62 (8.7) | 6.6–10.7 |
| Isoniazid + Rifampicin + Ofloxacin (Pre-XDR) | 4 (0.3) | 0.0–0.6 | 27 (3.8) | 2.4–5.2 |
| Isoniazid + Rifampicin + Kanamycin (Pre-XDR) | 1 (0.1) | 0.0–0.2 | 1 (0.1) | 0.0–0.4 |
| Isoniazid +Rifampicin + Ofloxacin +Kanamycin (XDR-TB) | 0 | - | 4 (0.6) | 0.0–1.1 |